Please take a moment to read Peter Pitts’ comments about the dangers of repackaging pharmaceuticals in Europe:
Repack Attack
Massive cross-border diversion in Europe (a.k.a. parallel trade) creates entry points for counterfeits or mishandled drugs. In fact, seizures of counterfeit drugs at the EU border rose 51 percent last year compared with 2006 according to a recent European Commission report. (See “medicines” data on page 18 of Report on Community Customs Activities on Counterfeit And Piracy.)
Nevertheless, repackaging by parallel importers and exporters in Europe can remove anti-counterfeiting security technology on a package, including the serial number. Huh??
Click here to read the official press release from the European Federation of Pharmaceutical Industries and Associations.
---
My review of Accenture’s track-and-trace report will appear tomorrow.
No comments:
Post a Comment